Alkermes reports Q4 non-GAAP EPS 22c, consensus 51c

Reports Q4 revenue $377.5M, consensus $362.02M. “We entered 2024 as a pure-play neuroscience company and are well positioned to deliver on our strategic priorities to drive growth of our proprietary commercial products, advance the clinical development of ALKS 2680 for the treatment of narcolepsy, and generate significant cash flow,” said CEO Richard Pops. “Our financial expectations for 2024 reflect our sharpened strategic focus and our work to position the business for sustained profitability and growth. As we look ahead, 2024 will be an important year as we focus on maintaining strong momentum in the launch of LYBALVI and advancing and expanding our development pipeline. We look forward to sharing our progress.”